Viking Therapeutics Inc. (VKTX)

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

VKTX remains a speculative, high-risk/reward play, with its future hinging on successful Phase III trial results for its obesity drug pipeline. The company's strong cash position and recent manufactur...

Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two leaders in this area, Eli Lilly and Novo Nordisk. However, several other companie...

Viking Therapeutics remains a promising weight-loss drug biotech due to the enrollment of new promising trials. The weight-loss sector's momentum has faded some, but Eli Lilly and Novo Nordisk have st...

Viking targets massive, validated markets with GLP-1/GIP and THR-β agonists, offering injectable and oral alternatives with promising Phase 2/3 results. Positioned as a second-line, tolerable, patient...

VKTX's VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given it will contain tho...

A major C-suite change at a potential competitor was a key factor behind the rise of Viking Therapeutics (VKTX 3.61%) stock on Friday, which closed the trading session 3% higher. That figure was well ...

Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.

One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in A...

Viking Therapeutics (VKTX 2.85%), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was a winning stock this week. Over the course of the past five trading days, its...